Biomechanical signals and the C-type natriuretic peptide counteract catabolic activities induced by IL-1β in chondrocyte/agarose constructs by Ramachandran, Manoj et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomechanical signals and the C-type natriuretic peptide
counteract catabolic activities induced by IL-1 in
chondrocyte/agarose constructs
Citation for published version:
Ramachandran, M, Achan, P, Salter, DM, Bader, DL & Chowdhury, TT 2011, 'Biomechanical signals and
the C-type natriuretic peptide counteract catabolic activities induced by IL-1 in chondrocyte/agarose
constructs' Arthritis research & therapy, vol. 13, no. 5, pp. R145. DOI: 10.1186/ar3459
Digital Object Identifier (DOI):
10.1186/ar3459
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Arthritis research & therapy
Publisher Rights Statement:
This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and
reproduction in any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
RESEARCH ARTICLE Open Access
Biomechanical signals and the C-type natriuretic
peptide counteract catabolic activities induced by
IL-1b in chondrocyte/agarose constructs
Manoj Ramachandran2, Prim Achan2, Donald M Salter3, Dan L Bader1 and Tina T Chowdhury1*
Abstract
Introduction: The present study examined the effect of C-type natriuretic peptide (CNP) on the anabolic and
catabolic activities in chondrocyte/agarose constructs subjected to dynamic compression.
Methods: Constructs were cultured under free-swelling conditions or subjected to dynamic compression with low
(0.1 to 100 pM) or high concentrations (1 to 1,000 nM) of CNP, interleukin-1b (IL-1b), and/or KT-5823 (inhibits cyclic
GMP-dependent protein kinase II (PKGII)). Anabolic and catabolic activities were assessed as follows: nitric oxide
(NO) and prostaglandin E2 (PGE2) release, and [
3H]-thymidine and 35SO4 incorporation were quantified by using
biochemical assays. Gene expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), aggrecan,
and collagen type II were assessed with real-time quantitative PCR (qPCR). Two-way ANOVA and the post hoc
Bonferroni-corrected t tests were used to examine data.
Results: CNP reduced NO and PGE2 release and partially restored [
3H]-thymidine and 35SO4 incorporation in
constructs cultured with IL-1b. The response was dependent on the concentration of CNP, such that 100 pM
increased [3H]-thymidine incorporation (P < 0.001). This is in contrast to 35SO4 incorporation, which was enhanced
with 100 or 1000 nM CNP in the presence and absence of IL-1b (P < 0.001). Stimulation by both dynamic
compression and CNP and/or the PKGII inhibitor further reduced NO and PGE2 release and restored [
3H]-thymidine
and 35SO4 incorporation. In the presence and absence of IL-1b, the magnitude of stimulation for [3H]-thymidine
and 35SO4 incorporation by dynamic compression was dependent on the concentration of CNP and the response
was inhibited with the PKGII inhibitor. In addition, stimulation by CNP and/or dynamic compression reduced IL-1b-
induced iNOS and COX-2 expression and restored aggrecan and collagen type II expression. The catabolic response
was not further influenced with the PKGII inhibitor in IL-1b-treated constructs.
Conclusions: Treatment with CNP and dynamic compression increased anabolic activities and blocked catabolic
effects induced by IL-1b. The anabolic response was PKGII mediated and raises important questions about the
molecular mechanisms of CNP with mechanical signals in cartilage. Therapeutic agents like CNP could be
administered in conjunction with controlled exercise therapy to slow the OA disease progression and to repair
damaged cartilage. The findings from this research provide the potential for developing novel agents to slow the
pathophysiologic mechanisms and to treat OA in the young and old.
Introduction
In healthy cartilage, chondrocytes mediate matrix remo-
delling through a balance in the synthesis and degrada-
tion of the extracellular matrix components. This
constant process is regulated by transient autocrine and
paracrine factors, which act through common pathways,
involving cytokines, signaling molecules, kinases, and
transcription factors, each of which is additionally influ-
enced by mechanical signals [1-6]. However, aging or
injury to the joint may trigger mechanical overload and
influence these pathways, leading to matrix damage and
osteoarthritis (OA) [7,8]. The identification of the sig-
nals that are activated during the different stages of the
disease process is highly challenging and involves
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examination of both molecular and mechanical factors.
To date, no successful chondroprotective or disease-
modifying therapies are available to intervene in this
pathological cycle and help to restore joint function.
Thus, agents for promoting biophysical and therapeutic
strategies to slow the pathophysiologic mechanisms and
treat OA are under active investigation.
As an example, the C-type natriuretic peptide (CNP)
has recently emerged as an important anabolic regulator
of cartilage [9-11]. Indeed, stimulation of chondrocytes
with CNP has been reported to increase collagen and
proteoglycan synthesis and to enhance cell proliferation
[12-14]. Moreover, the guanylyl cyclase B and intracellu-
lar 3,5’-cyclic guanosine monophosphate (GC-B/cGMP)
pathway was shown to mediate the increase of cell pro-
liferation in rat chondrocytes treated with CNP [15,16].
Upregulation of the GC-B/cGMP system by CNP is
essential for cartilage development and involves cyclic
GMP-dependent protein kinase II (PKGII) mechanisms
in late proliferative and pre-hypertrophic zones of
growth-plate cartilage [9,17-19]. Indeed, targeted disrup-
tion of the genes encoding CNP and PKGII results in
impaired growth of endochondral bones and leads to
severe dwarfism and skeletal defects [9,17,18]. Conver-
sely, overexpression of CNP results in skeletal over-
growth and rescued dwarfism in a murine model of
human achondroplasia [20]. Consequently, growing evi-
dence suggests that stimulation of CNP signaling may
contribute to anabolic events and potentially provide a
new therapeutic application for conditions with loss of
cartilage matrix and in the treatment of skeletal growth
disorders.
Numerous studies have shown that chondrocytes from
many species produce nitric oxide (NO) and prostaglan-
din E2 (PGE2) release, via induction of the inducible
nitric oxide synthase (iNOS) and cyclooxygenase (COX-
2) enzymes, in response to interleukin-1b (IL-1b) and
tumor necrosis factor alpha (TNF-a) [21-24]. These
pro-inflammatory cytokines are involved in the patho-
genesis of OA, but their regulation by mechanical sig-
nals is necessarily complex. For example, in vitro
mechanical conditioning experiments demonstrate that
mechanical signals, representing a controlled physiologi-
cal activity, inhibit IL-1b-induced iNOS and COX-2
expression and restore matrix synthesis [25,26]. The
opposite effect was found for mechanical signals, which
could be interpreted as an excessive or injurious
response, and enhanced the IL-1b-induced catabolic
response [27]. These findings indicate that mechanical
signals that mimic the physiological loading environ-
ment of cartilage act in an anti-inflammatory manner
and could therefore provide a physical strategy to repair
damaged tissue [28,29]. Our data concur with clinical
findings that demonstrate the beneficial effects of
prescribed rehabilitative therapies for reducing inflam-
mation and improving joint function in patients with
knee OA [30-32]. However, no agreement has been
achieved on whether controlled exercise therapy could
be efficacious in the aging population [33]. Conse-
quently, restoration of chondrocyte function with CNP
in combination with physical therapies may promote
cartilage health in the OA joint.
These observations raise the possibility for the poten-
tial therapeutic effects of both CNP and mechanical sti-
muli in reducing the cytokine-induced catabolic events
in OA. However, very little is known about the molecu-
lar mechanisms activated by CNP and their role in sti-
mulating matrix production in OA chondrocytes. No
studies have investigated the interactions of mechanical
loading with the CNP pathway or whether they compete
with catabolic pathways induced by cytokines. The pre-
sent study therefore examines the effect of CNP and
mechanical loading on anabolic and catabolic activities
in chondrocyte/agarose constructs stimulated with IL-
1b.
Materials and methods
Chondrocyte isolation and culture in agarose constructs
Human cartilage was obtained from nine patients (age
35 to 58 years), with ethical approval (East London and
The City Research Ethics Committee) and informed
patient consent, undergoing total knee arthroplasty at
the Royal London Hospital, Barts, and the London NHS
Trust, London, UK. Cartilage was removed from the
femoral condyles and tibial plateaus. The morphology of
the cartilage specimens was graded for gross degenera-
tive changes according to the ICRS classification, and
tissues that represent normal (grade 0 or 1) and early
(grade 2) OA were used for experiments. Each experi-
mental condition was repeated with chondrocytes from
three to four different donors. Cartilage tissue was diced
and incubated on rollers for 1 hour at 37°C in Dulbecco
Modified Eagle Medium (DMEM) supplemented with
10% (vol/vol) Fetal Calf Serum (FCS) + 2 μM L-gluta-
mine, 5 μg/ml penicillin, 5 μg/ml streptomycin, 20 mM
Hepes buffer, and 0.05 mg/ml L-ascorbic acid + 700
unit/ml pronase and incubated for a further 16 hours at
37°C in DMEM + 10% FCS, supplemented with 100
units/ml collagenase type XI (Sigma-Aldrich, Poole,
UK). The cell suspension was washed and viable chon-
drocytes counted using a hemocytometer and trypan
blue. Cells were finally resuspended in medium at a cell
concentration of 8 × 106 cells/ml by using well-estab-
lished methods [34,35]. In brief, the cell suspension was
added to an equal volume of molten 6% (wt/vol) agarose
type VII in Earle Balanced Salt Solutions (EBSS) to yield
a final cell concentration of 4 × 106 cells/ml in 3% (wt/
vol) agarose (Sigma-Aldrich, Poole, UK). The
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chondrocyte/agarose suspension was transferred into a
sterile stainless steel mold, containing holes 5 mm in
diameter and 5 mm in height and allowed to gel at 4°C
for 20 minutes. Constructs were cultured in a defined
culture medium comprising DMEM, 0.1 μM dexametha-
sone, 0.17 mM ascorbate, 1 mM sodium pyruvate, 0.35
mM proline, 5 μg/ml penicillin, 5 μg/ml streptomycin,
20 mM Hepes buffer, 2 μM L-glutamine, ITS, and sup-
plements (6.25 μg/ml insulin, 6.25 μg/ml transferrin,
6.25 μg/ml seleneous acid, 5.33 μg/ml linoleic acid, and
1.25 μg/ml bovine serum albumin) at 37°C in 5% CO2
for 24 hours (all from Cambrex Bioscience, Wokingham,
UK).
Dose-response effect of CNP in chondrocyte/agarose
constructs
The dose-response effect of CNP was examined in con-
structs cultured under free-swelling conditions to deter-
mine the appropriate concentration for mechanical
loading studies. Constructs were cultured in 1 ml of
defined media supplemented with either low (0, 0.1, 1,
10, 100 pM) or high (0, 1, 10, 100, 1000 nM) concentra-
tions of CNP in the presence and absence of 10 ng/ml
IL-1b and/or 5 μM KT5823 for 48 hours (all from
Sigma-Aldrich). KT5823 inhibits PKGII by competing
directly with ATP at the catalytic domain. In each case,
the medium was additionally supplemented with 1 μCi/
ml [3H]-thymidine and 10 μCi/ml 35 SO4 (both Amer-
sham Biosciences Ltd, Bucks, UK) for the assessment of
cell proliferation and proteoglycan synthesis, respec-
tively. At the end of the culture period, the constructs
and corresponding media were immediately stored at
-20°C before biochemical analysis.
Application of dynamic compression
In separate experiments, a fully characterized bioreactor
compression system (Zwick Testing Machines, Leomin-
ster, UK) was used to determine the effect of CNP and
dynamic loading on cell metabolism and gene expres-
sion in chondroycte/agarose constructs. The bioreactor
has been extensively described previously [34-36]. To
review briefly, equilibrated constructs were transferred
into individual wells of a 24-well culture plate (Costar,
High Wycombe, UK) and mounted within the bioreac-
tor. One milliliter of defined media supplemented with
0 or 10 ng/ml IL-1b in the presence and absence of low
(100 pM) or high (100 nM) concentrations of CNP and/
or 5 μM KT5823 were introduced into each well.
Strained constructs were subjected to dynamic compres-
sion ranging from 0 to 15% strain in a sinusoidal wave-
form at a frequency of 1 Hz. The compression regimen
was applied in an intermittent manner, with a profile of
1.5 hour compression followed by a 4.5 hour unstrained
period for both the 6 and 48 hour culture periods. This
resulted in duty cycles equivalent to 5400 and 43200,
respectively. Control constructs were maintained in an
unstrained state within the bioreactor system and cul-
tured for the same time period. At the end of the cul-
ture period, the constructs and corresponding media
were immediately stored at -70°C before analysis.
RNA isolation, cDNA synthesis, and real-time qPCR
RNA was isolated from chondrocytes cultured in agar-
ose by using protocols described in the QIAquick Spin
gel extraction and RNeasy kits, as previously described
(Qiagen, West Sussex, UK) [28,37]. By following manu-
facturer’s instructions, Ambion’s DNA-free DNase treat-
ment and removal reagents were used to eliminate any
contaminating DNA from the RNA sample (Ambion
Applied Biosystems, Warrington, UK). RNA was quanti-
fied on the Nanodrop ND-1000 spectrophotometer
(LabTech, East Sussex, UK), and reverse transcription
was performed by using manufacturer’s protocols from
the Enhanced Avian RT First Strand cDNA synthesis
kit, oligo(dT)23 primer, and a total of 200 ng of RNA
(Sigma Genosys, Cambridge, UK). Real-time quantitative
PCR assays coupled with LNA probes were performed
in 25-μl reaction mixtures containing 1 μl cDNA, 12.5
μl JumpStart Taq PCR Master Mix, primer pairs, and
probes detailed in Table 1 and nuclease-free PCR-grade
water to 25 μl (Sigma Genosys, Cambridge, UK). Each
sample was run in duplicate on the 96-well thermal sys-
tem of the Mx3000P quantitative PCR instrument (Stra-
tagene, Amsterdam, The Netherlands). Thermocycling
conditions comprised an initial polymerase activation
step at 95°C for 3 minutes, followed by denaturation of
35 cycles at 95°C for 30 seconds, annealing at 55°C for 1
minute, and extension at 72°C for 1 minute. PCR effi-
ciencies for optimal primer pair and probe concentra-
tions were derived from standard curves (n = 3) by
preparing a 10-fold serial dilution of cDNA from a sam-
ple that represented the untreated control at time-zero
conditions. The real-time PCR efficiencies (E) of amplifi-
cation for each target was defined according to the rela-
tion, E = 10[-1/slope]. The R2 value of the standard curve
exceeded 0.9998 and revealed efficiency values presented
in Table 1.
Fluorescence data were collected during the annealing
stage of amplification, and data were analyzed on the
MxPro qPCR software (version 3, Stratagene). Baselines
and thresholds were automatically set by the RG-3000
qPCR software and used after manual inspection. The
cycle threshold (Ct) value for each duplicate reaction
was expressed as the mean value, and the results were
exported into Microsoft Excel for further analysis. The
data obtained by PCR assay for GAPDH were validated
as a reference gene by displaying the Ct values as box-
and-whisker plots, and the distribution examined under
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mechanical loading conditions (data not shown). The Ct
values for GAPDH remained stable, with no changes
detected under all culture conditions, suggesting its suit-
ability as a reference gene. Relative quantification of
iNOS, COX-2, aggrecan, and collagen type II signals
were accomplished by normalizing each target to the
reference gene, GAPDH, and to the calibrator sample by
a comparative Ct approach. For each sample, the ratio
of target ΔCt and reference ΔCt was calculated, as pre-
viously described [28,37].
Biochemical analysis
The production of NO was determined in media by
converting nitrate to nitrite by using 1 unit/ml nitrate
reductase in 40 μM NAPDH, 500 μM glucose 6-phos-
phate, 160 unit/ml glucose 6-phosphate dehydrogenase
and 20 mM Tris-HCL for 15 minutes at 37°C. Total
nitrite was assayed spectrophotometrically at 540 nm by
using the Griess reaction. PGE2 production was mea-
sured in the culture media by using a high-sensitivity
enzyme immunoassay according to manufacturer’s
instructions (Amersham Biosciences Ltd, Bucks, UK).
[3H]-thymidine incorporation was measured in con-
structs digested overnight at 37°C with 10 U/ml agarase
followed by 1 hour at 60°C with 2.8 U/ml papain (both
Sigma Chemical Co., Poole, UK) and analyzed with 10%
trichloroacetic acid precipitation onto filters by using a
Millipore Multiscreen system (Millipore, Watford, UK),
as previously described [29,34,35]. Incorporation of
35SO4 was determined in both agarase/papain digests
and the culture media by using the Alcian blue precipi-
tation method, as previously described [29,34,35]. Total
DNA content remained stable throughout the culture
conditions was assayed by using the Hoescht dye 33258
in agarose/papain digests.
Statistics
For dose-response studies, data represent the mean and
SEM values of six replicates from three separate experi-
ments. For the mechanical loading experiments, bio-
chemical and gene-expression data represent the mean
and SEM values of eight replicates from three separate
experiments. Statistical analysis was performed with a
two-way analysis of variance (ANOVA) and the multiple
post hoc Bonferroni-corrected t tests to compare differ-
ences between the various treatment groups, as indi-
cated in the figure legend. For gene-expression data,
ratio values were log transformed before analysis by a
two-way ANOVA and the post hoc Bonferroni-corrected
t test. In all cases, a level of 5% was considered statisti-
cally significant (P < 0.05).
Results
CNP differentially regulates cell metabolism in a dose-
dependent manner
Chondrocytes cultured in agarose constructs produce
significant amounts of NO and PGE2 release in response
to IL-1b (both P values < 0.001; Figure 1a and 1b,
Table 1 Description of the LNA probe and primer sequences used to quantify gene expression
Gene Gene ID Sequences Product length Efficiency
iNOS 4843 Probe: 5’-FAM-ACTTCTTTCCCGTCTCC-BHQ1-3’ 305 1.99
± 0.8
Sense: 5’-TCCAGATAAGTGACATAAGTG-3’
Antisense: 5’-CAGCTTGACCAGAGATTC-3’
COX-2 5743 Probe: 5’-AAACTGCTCAACACCG-BHQ1-3’ 216 1.99
± 2.8
Sense: 5’- GGACAGGATTCTATGGAG-3’
Antisense: 5’- GGATGTCAACACATAACTC-3’
Aggrecan 176 Probe: 5-’FAM-CCAACTCTTCAAGGTGA-BHQ1-3’ 109 1.98
± 0.4
Sense: 5’-GACTGAAGTTCTTGGAGAA-3’
Antisense: 5’-CACGAAAACCCAGAGTAA-3’
Collagen type II 1280 Probe: 5’-FAM-TCTGTCTCCTTGCTTGCCA-BHQ1-3’ 200 1.99
± 0.9
Sense: 5’-GGAGTCAAGGGTGATCGT-3’
Antisense: 5’-CTTGTGCACCAGCTTCTC-3’
GAPDH 2597 Probe: 5’-HEX-CAGTCAGCCGCATCTTCT-BHQ1-3’ 160 1.98
± 4.3
Sense: 5’-TCTCTGCTCCTCCTGTTC-3’
Antisense: 5’-CGCCCAATACGACCAAAT-3’
Primers used in PCR experiments with Locked Nucleic Acid (LNA) probes produced amplicons between 109 and 305 base pairs and efficiency values between
1.98 and 1.99. Probes contain fluorescein (FAM) or 6-carboxyhexafluorescein (HEX) as the 5’-reporter dye and Black Hole Quencher 1 (BHQ1) as the 3’-quencher.
Nucleotides highlighted in bold denote the LNA base.
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respectively). To examine whether CNP and the selec-
tive PKGII inhibitor could influence the IL-1b-induced
NO and PGE2 release, constructs were cultured with IL-
1b and CNP at concentrations ranging from 0.1 to 100
pM in the presence and absence of KT5823. It was evi-
dent that CNP reduced IL-1b induced NO and PGE2
release in a dose-dependent manner, with maximal inhi-
bition at 10 and 100 pM when compared with IL-1b-
treated constructs (all P < 0.001). Treatment with IL-1b
and the PKGII inhibitor did not influence NO and PGE2
levels in constructs cultured with CNP (Figures 1a and
1b). In the absence of IL-1b, CNP increased [3H]-thymi-
dine incorporation in a dose-dependent manner (P <
0.01; Figure 1c), whereas this effect of CNP was reduced
by IL-1b and/or KT5823 (P < 0.01). At 100 pM, CNP
increased 35SO4 incorporation (P < 0.05; Figure 1d), and
this effect was reduced by IL-1b (P < 0.001) and not
further influenced with KT5823.
Figure 2 presents the dose-response effects of CNP
at concentrations ranging from 0.1 to 1000 nM in
constructs cultured with IL-1b and/or KT5823 (Figure
2). IL-1b-induced NO and PGE2 release was reduced
by CNP in a dose-dependent manner (Figure 2a).
However, the effect was most pronounced in the pre-
sence of 1 nM CNP, which completely abolished the
IL-1b-induced PGE2 release (P < 0.001; Figure 2b).
Treatment with CNP and the PKGII inhibitor had no
further effect on the reduction of IL-1b-induced
release of both NO and PGE2. At 1 nM, CNP
increased [3H]-thymidine incorporation when com-
pared with untreated controls (P < 0.05; Figure 2c).
The presence of IL-1b inhibited [3H]-thymidine incor-
poration and the response was not significantly influ-
enced by CNP and/or the PKGII inhibitor (Figure 2c).
In contrast, CNP increased 35SO4 incorporation in a
dose-dependent manner with maximal stimulation at
100 and 1000 nM (P < 0.001; Figure 2d). The presence
of IL-1b inhibited 35SO4 incorporation, and the levels
were enhanced with CNP at 100 and 1000 nM, only.
However, stimulation of 35SO4 incorporation by CNP
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in IL-1b-treated constructs was abolished in the pre-
sence of the PKGII inhibitor (P < 0.001; Figure 2d).
CNP and dynamic compression counteract IL-1b-induced
NO and PGE2 release and restore cell proliferation and
proteoglycan synthesis
In separate experiments, the effects of CNP and
dynamic compression were examined in constructs cul-
tured with IL-1b and/or the PKGII inhibitor by using
either low (100 pM) or high (100 nM) concentrations of
the peptide (Figure 3). In the absence and presence of
CNP, dynamic compression reduced NO release (P <
0.001; Figure 3a) but had no significant effect on PGE2
levels (Figure 3b). In unstrained constructs, the presence
of IL-1b increased NO and PGE2 release, and the
response was reduced by dynamic compression, CNP,
and/or both stimuli (all P < 0.001). Stimulation with
CNP and/or dynamic compression in the presence of
the PKGII inhibitor further reduced NO and PGE2
release in IL-1b-treated constructs (both P < 0.01; Fig-
ure 3a and 3b, respectively). In contrast, dynamic
compression increased [3H]-thymidine incorporation in
the presence and absence of CNP (P < 0.001; Figure 3c).
This effect was inhibited with IL-1b and could be
reversed by stimulation with 100 pM CNP, dynamic
compression, or both. The presence of the PKGII inhibi-
tor blocked CNP-induced stimulation of [3H]-thymidine
incorporation in IL-1b-treated constructs. The opposite
effect was found for 35SO4 incorporation, whereby sti-
mulation with 100 nM CNP and dynamic compression
induced the greatest response when compared with
untreated controls or constructs cultured with 100 nM
CNP (P < 0.001; Figure 3d). The IL-1b-induced inhibi-
tion of 35SO4 incorporation was reversed by both 100
nM CNP and dynamic compression (P < 0.001) and
inhibited with KT5823 (Figure 3d).
CNP and dynamic compression modulate IL-1b-induced
gene expression
To investigate the effect of CNP on the expression of
catabolic and anabolic genes, constructs were subjected
to dynamic compression over 6 and 48 hour period in
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the presence and absence of low (100 pM) and high
(100 nM) concentrations of the peptide (Figure 4). In
unstrained constructs, IL-1b induced iNOS and COX-2
expression at 6 and 48 hours (all P < 0.001; Figure 4a
and 4b, respectively). At 6 and 48 hours, the IL-1b-
induced iNOS and COX-2 expression was inhibited by
dynamic compression (both P < 0.001) or by the pre-
sence of low (both P < 0.01) or high concentrations of
CNP (both P < 0.01). A combination of dynamic com-
pression and CNP reduced iNOS and COX expression
at 6 hours, with levels returning to basal values with IL-
1b at 48 hours. This effect was not significantly influ-
enced further with KT5823 in constructs cultured with
IL-1b and CNP. In contrast, dynamic compression
increased aggrecan and collagen type II expression at 6
hours but not at 48 hours (both P < 0.05; Figure 4c and
4d, respectively). In unstrained constructs, stimulation
with CNP increased aggrecan and collagen type II
expression in a concentration-dependent manner and
the effect was further enhanced with dynamic compres-
sion at either 6 or 48 hours. In unstrained constructs,
IL-1b inhibited aggrecan and collagen type II expression
and the effect was reversed with dynamic compression
(P < 0.001), 100 nM CNP (P < 0.05), or both at 6 (P <
0.01) and 48 hours (P < 0.05) for aggrecan expression.
In contrast, stimulation by 100 pM or 100 nM CNP and
dynamic compression reversed the IL-1b-induced inhibi-
tion of collagen type II expression at 6 (both P < 0.01)
and 48 hours (both P < 0.05; Figure 4d). The compres-
sion-induced stimulation of aggrecan and collagen type
II expression was inhibited with KT5823 in constructs
cultured with IL-1b and CNP.
Discussion
CNP is expressed in the growth plate and regulates
endochondral ossification through increased cell prolif-
eration and hypertrophy and stimulates production of
cartilage matrix proteins [13,14,19,38,39]. The molecular
mechanisms that control these processes are not com-
pletely understood. In addition, it is unclear whether the
effects of CNP in adult cartilage are influenced by
mechanical signals that modulate matrix synthetic
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activity and inflammatory pathways. However, the
response to mechanical signals, in part, is dependent on
the type of mechanical loading regime, its duration, and
whether loading was applied during the early or late
stage of the disease process. Consequently, stimulation
of chondrocytes with natriuretic peptides and mechani-
cal signals may potentially serve to modulate cell prolif-
eration and increase matrix synthesis in the OA joint.
The present study therefore examined the effect of CNP
and mechanical signals in an in vitro inflammatory
chondrocyte/agarose model.
Initial studies examined the dose-response effect of
CNP on cell proliferation and proteoglycan synthesis
and whether the peptide could stimulate anabolic
activities by blocking the catabolic mediators induced by
IL-1b. In the absence of the cytokine, low concentra-
tions of CNP (10 to 100 pM) increased cell proliferation
without affecting proteoglycan synthesis in chondrocyte/
agarose constructs. The opposite effect was found for
high concentrations of CNP (100 to 1000 nM), which
increased proteoglycan synthesis without any significant
change in cell proliferation. Our data are in agreement
with previous studies that demonstrate differential
effects of CNP in chondrocytes cultured in monolayer
[13,14]. Other studies have shown that stimulation by
CNP increased cell proliferation in growth-plate chon-
drocytes and chondrogenic cell lines and enhanced
GAG synthesis and cell-adhesion molecules in
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mesenchymal cells [39-41]. In addition, CNP increased
the expression of genes involved in proteoglycan synth-
esis and inhibited the expression of proteinase enzymes
involved in matrix breakdown [12,39,41]. CNP therefore
plays a significant role in regulating chondrocytes and
contributes to the structural properties of cartilage tis-
sue [15,40,42]. However, CNP has never been implicated
in OA and the importance of this pathway in chondro-
cytes is not known. In the present study, biochemical
analysis revealed that under IL-1b conditions, CNP inhi-
bits NO and PGE2 production in a dose-dependent
manner and restores cell proliferation and proteoglycan
synthesis. The reparative effect involved PKGII-depen-
dent mechanisms and was influenced by the concentra-
tion of CNP, resulting in greater levels of matrix
synthesis with nanomolar concentrations in IL-1b-trea-
ted constructs. In contrast, picomolar concentrations of
CNP increased cell proliferation in the presence of IL-
1b, and the response was blocked with the PKGII inhibi-
tor. A recent study showed that CNP can induce hyper-
trophy in chondrocytes, which may contribute to OA
disease progression [43,44]. In the present study, stimu-
lation with CNP resulted in differential effects, such that
low doses increased gene expression of type I collagen,
type × collagen, and MMP-13 without affecting collagen
type II mRNA (Table 2). In contrast, high concentra-
tions had the opposite effect and increased type II col-
lagen gene expression and inhibited type I collagen and
MMP-13 in free-swelling constructs (Table 2). Whilst
the CNP and PKGII pathways might be used in the
treatment of growth retardation, concentration-depen-
dent effects of CNP should be further addressed to
ensure that their potential damaging effects of CNP are
not evoked in cartilage.
Both CNP and NO stimulate the synthesis of cGMP
and lead to activation of common downstream path-
ways, involving PKGII. In the present study, the PKGII
inhibitor did not influence the levels of NO and PGE2
release following CNP and/or IL-1b treatment, implicat-
ing alternative mechanisms. For example, the cGMP
pathways are likely to cross-talk with the catabolic path-
ways because of elevated levels of NO induced by IL-1b.
More specifically, NO binds to the heme-containing
soluble protein, guanylyl cyclase (sGC), and stimulates
cGMP levels, which contribute to the production of
PKG and cGMP-regulated phosphodiesterase (PDE) sub-
types [45]. NO will change the function of other heme-
containing proteins, such as COX-2 and increase PGE2
production. In a previous study, overstimulation of the
PKGI pathway was shown to block IGF-1-induced pro-
teoglycan synthesis in chondrocyte monolayers [46].
Indeed, it was previously reported with human chondro-
cytes that enhanced cGMP levels lead to alterations in
the PDE5 subtype and matrix breakdown. This effect
was mediated by the induction of iNOS and NO release
with IL-1b [47]. This is in contrast to chemical inhibitor
studies for PDE4, which showed a partial inhibition of
NO release in OA chondrocytes [48]. Thus, pharmaco-
logic inhibitors selective for PDE subtypes may reduce
the catabolic response in chondrocytes. Some evidence
indicates a functional role of PDE4 in downregulating
the IGF-1-binding proteins, which are known to contri-
bute to OA pathogenesis [49-51]. The action of elevated
cytokine-induced NO/cGMP pathways and complex
interplay with CNP is unknown and requires further
investigation.
It is well established that NO and PGE2 accelerate
chondrocyte-mediated matrix degradation, inflamma-
tion, and apoptosis [1,52]. NO is also an important sig-
naling molecule in cartilage in response to different
stimuli, including pro-inflammatory cytokines and
mechanical signals [7,26,28]. We therefore examined
whether mechanical signals could influence NO and
PGE2 levels in chondrocyte/agarose constructs cultured
with IL-1b and either low (100 pM) or high (100 nM)
concentrations of CNP. In the presence and absence of
IL-1b, stimulation with mechanical signals and CNP
induced the expression of aggrecan and collagen type II
and increased cell proliferation and proteoglycan synth-
esis in a concentration-dependent manner. The anabolic
Table 2 Effect of CNP on gene expression in chondrocyte/agarose constructs
100 pM 100 nM
UT IL-1b CNP IL-1b + CNP IL-1b + CNP + KT5823 CNP IL-1b + CNP IL-1b + CNP + KT5823
Culture period (hr) 6 48 6 48 6 48 6 48 6 48 6 48 6 48 6 48
Collagen type I a a ND ND ↑b ↑c ND ND ND ND a ↓d ND ND ND ND
Collagen type II ↑b a ↓d ↓d a a a a a a a ↑c ↓d ↓d a a
Col X a a a a ↑b ↑c ↑ b ↑ c ↓ d ↓d a a a a a a
Sox-9 a a ND ND a a ND ND ND ND ↑b ↑c ND ND ND ND
MMP-13 a a ↑b ↑c ↑b ↑b ↑b ↑c ↓d ↓d a a ↓d ↓d a a
aNo significant change; ↑b, a significant increase (P < 0.05); ↑c, a significant increase (P < 0.01); ↓d, a significant decrease (P < 0.05); ND, not determined.
Chondrocyte/agarose constructs were cultured with low (100 pM) or high (100 nM) concentrations of CNP with 0 or 10 ng/ml IL-1b and/or 5 μM KT5823 for 6
and 48 hours (n = 8). Note that statistical comparisons were determined for the following samples: Time = 0 versus 6 or 48 hr (UT); UT versus IL-1b; UT versus
CNP; IL-1b versus IL-1b + CNP; IL-1b + CNP versus IL-1b + CNP + KT5823.
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response was blocked by the PKGII inhibitor. It is plau-
sible that PKGII represents the principal mediators of
cGMP signals and therefore has a positive role in carti-
lage homeostasis. In the presence of IL-1b, both
mechanical signals and CNP reduced iNOS and COX-2
expression and NO and PGE2 production. This is the
first study to show that CNP and mechanical signals
block catabolic activities and rescue anabolic events in
chondrocyte/agarose constructs cultured with IL-1b.
These findings open the possibility of using CNP in the
treatment of damaged cartilage in conjunction with con-
trolled levels of mechanical loading. Some evidence in
chondrocytes suggests that physiological mechanical sig-
nals stimulate production and secretion of growth fac-
tors, substance P, and IL-4 that mediate extracellular
matrix synthesis and remodelling [3]. CNP additionally
mediates matrix response through regulation of cGMP
regulated ion channels (CGi) [51]. These cyclic nucleo-
tide-gated channels belong to the superfamily of vol-
tage-gated ion channels that regulate membrane
potentials and could evoke calcium (Ca2+) entry in
chondrocytes [53,54]. We previously showed that the
stretch-activated (SA) ion channels and the integrins
mediate mechanical loading induced calcium signaling
and regulate anabolic and catabolic pathways in chon-
drocytes [3,28,55,56]. The contrasting effects are due in
part to different temporal dynamics and magnitude of
the kinases and transcription factors, which are influ-
enced by the cytokines or mechanical loading. Thus,
further studies should examine the molecular pathways
induced by CNP and mechanical signals in inflammatory
chondrocytes. The proposed interactions of CNP with
mechanical signals are illustrated in Figure 5.
In summary, CNP treatment leads to significant
increases in anabolic activities and the reduction of cata-
bolic mediators in the presence of IL-1b. The anabolic
response was PKGII mediated and could be enhanced
by mechanical signals in a synergistic manner. The cata-
bolic response was not influenced by the PKGII inhibi-
tor, implicating alternative mechanisms involving the
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Figure 5 Proposed signaling interactions between CNP and mechanical signals in chondrocytes. C-type natriuretic peptide (CNP) binding
to the natriuretic peptide receptor-B (NPR-B) activates the extracellular domain of guanylyl cyclase B (GC-B), leading to increased levels of 3,5’-
cyclic guanosine monophosphate (cGMP). The accumulation of cGMP levels modulates the downstream activities of cGMP-dependent protein
kinases (PKGI and II), cGMP-regulated ion channels (CGi), and cGMP-regulated phosphodiesterase (PDE) subtypes. PKGII mediates matrix synthesis
augmented by mechanical signals that influence CGi ion channels. However, the cGMP pathways are likely to crosstalk with the catabolic
pathways because of elevated levels of nitric oxide (NO) induced by interleukin-1b (IL-1b). More specifically, NO binds to the heme-containing
soluble protein, guanylyl cyclase (sGC), and stimulates cGMP levels, which contribute to the production of PKGI or PDE subtypes, leading to
matrix breakdown.
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PDEs. Further studies will examine the relation between
CNP and mechanical loading in detail, because these
signals converge on a common mediator, cGMP. For
instance, because NO is an established player in mediat-
ing both mechanical and inflammatory signals in carti-
lage, we will determine which components of the CNP
and mechanical loading pathways interfere with the
cytokine-induced NO pathway and whether these factors
directly regulate each other or cross-talk with other sig-
naling routes.
Conclusions
Therapeutic agents like CNP could be administered in
conjunction with controlled exercise therapy to slow
OA disease progression and maintain cartilage health.
The findings from this research provide the potential for
developing a novel agent to slow the pathophysiologic
mechanisms and to treat OA in the young and old.
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